Hangzhou Diagens Biotechnology Co., Ltd. (HKG:2526)
Hong Kong · Delayed Price · Currency is HKD 526.00
+104.20 (24.70%)
Aug 21, 2026, 4:08 PM HKT
HKG:2526 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| 183.31 | 164.42 | 70.35 | 52.84 | |
Revenue Growth | - | 133.72% | 33.13% | - |
Cost of Revenue | 55.35 | 46.34 | 24.29 | 15.35 |
Gross Profit | 127.97 | 118.09 | 46.06 | 37.5 |
Selling, General & Admin | 100.68 | 84.74 | 50.57 | 51.84 |
Research & Development | 130.15 | 104.35 | 25.52 | 28.64 |
Other Operating Expenses | 13.06 | 9.57 | 2.07 | 1.2 |
Operating Expenses | 243.89 | 198.66 | 78.15 | 81.68 |
Operating Income | -115.92 | -80.57 | -32.09 | -44.19 |
Interest Expense | -0.73 | -0.58 | -21.19 | -16.32 |
Interest & Investment Income | 0.52 | 0.52 | 0.77 | 1.61 |
Earnings From Equity Investments | 0.02 | 0.03 | -0.1 | -0 |
Currency Exchange Gain (Loss) | -12.13 | 0.04 | 0.06 | 0.04 |
Other Non Operating Income (Expenses) | -7.61 | -0.75 | 0.16 | 2.36 |
EBT Excluding Unusual Items | -135.85 | -81.31 | -52.39 | -56.5 |
Gain (Loss) on Sale of Investments | 0.31 | 0.31 | 0.33 | 0.19 |
Gain (Loss) on Sale of Assets | 2.2 | 2.2 | 0.18 | - |
Other Unusual Items | 11.67 | 11.67 | 8.5 | 0.13 |
Pretax Income | -121.67 | -67.14 | -43.39 | -56.18 |
Income Tax Expense | 0.01 | 0 | -0.01 | -0.07 |
Net Income | -121.68 | -67.14 | -43.38 | -56.12 |
Net Income to Common | -121.68 | -67.14 | -43.38 | -56.12 |
Net Income Growth | - | - | - | - |
Shares Outstanding (Basic) | 83 | 80 | 79 | 76 |
Shares Outstanding (Diluted) | 83 | 80 | 79 | 76 |
Shares Change | - | 1.31% | 3.69% | - |
EPS (Basic) | -1.47 | -0.84 | -0.55 | -0.74 |
EPS (Diluted) | -1.47 | -0.84 | -0.55 | -0.74 |
EPS Growth | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Free Cash Flow | -156.08 | -58 | -53.98 | -71.61 |
Free Cash Flow Per Share | -1.88 | -0.72 | -0.68 | -0.94 |
Gross Margin | 69.81% | 71.82% | 65.47% | 70.95% |
Operating Margin | -63.24% | -49.00% | -45.62% | -83.62% |
Profit Margin | -66.38% | -40.83% | -61.65% | -106.19% |
Free Cash Flow Margin | -85.15% | -35.28% | -76.72% | -135.52% |
EBITDA | -109.12 | -71.96 | -21.22 | -39.47 |
EBITDA Margin | -59.53% | -43.77% | -30.16% | -74.69% |
D&A For EBITDA | 6.8 | 8.61 | 10.88 | 4.72 |
EBIT | -115.92 | -80.57 | -32.09 | -44.19 |
EBIT Margin | -63.24% | -49.00% | -45.62% | -83.62% |